Search

Your search keyword '"Farsang, C"' showing total 347 results
Start Over Author "Farsang, C"
347 results on '"Farsang, C"'

1. Indications for and utilization of angiotensin receptor II blockers in patients at high cardiovascular risk

Author

Farsang C

Subjects
Angiotensin II receptor blocker, cardiovascular disease, cardiometabolic risk, cardiovascular prevention, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Csaba FarsangCardiometabolic Center, Department of Internal Medicine, St Imre Hospital, Budapest, HungaryAbstract: The worldwide burden of cardiovascular disease is growing. In addition to lifestyle changes, pharmacologic agents that can modify cardiovascular disease processes have the potential to reduce cardiovascular events. Antihypertensive agents are widely used to reduce the risk of cardiovascular events partly beyond that of blood pressure-lowering. In particular, the angiotensin II receptor blockers (ARBs), which antagonize the vasoconstrictive and proinflammatory/pro-proliferative effects of angiotensin II, have been shown to be cardio vascularly protective and well tolerated. Although the eight currently available ARBs are all indicated for the treatment of hypertension, they have partly different pharmacology, and their pharmacokinetic and pharmacodynamic properties differ. ARB trials for reduction of cardiovascular risk can be broadly categorized into those in patients with/without hypertension and additional risk factors, in patients with evidence of cardiovascular disease, and in patients with severe cardiovascular disease, such as heart failure. These differences have led to their indications in different populations. For hypertensive patients with left ventricular hypertrophy, losartan was approved to have an indication for stroke prevention, while for most patients at high-risk for cardiovascular events, telmisartan is an appropriate therapy because it has a cardiovascular preventive indication. Other ARBs are indicated for narrowly defined high-risk patients, such as those with hypertension or heart failure. Although in one analysis a possible link between ARBs and increased risks of cancer has surfaced, several meta-analyses, using the most comprehensive data available, have found no link between any ARB, or the class as a whole, and cancer. Most recently, the US Food and Drug Administration completed a review of the potential risk of cancer and concluded that treatment with an ARB medication does not increase the risk of developing cancer. This review discusses the clinical evidence supporting the different indications for each of the ARBs and the outstanding safety of this drug class.Keywords: angiotensin II receptor blocker, cardiovascular disease, cardiometabolic risk, cardiovascular prevention

Published
2011

8. Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study

Author

Aronson, Doron, Verbalis, Joseph G., Mueller, Matthias, Krum, Henry, Alvarisqueta, A., Blüguermann, J., Guerrero, R.A. Ahuad, Howes, L., Krum, H., Sindone, A., Decaux, G, Soupart, A., El Allaf, D., Baillie, F., Racine, N., Logsetty, S., Morales, Á., Gutierrez, F., Gadsbøll, N., Dervenis, C., Manolis, A., Tsiftsis, D., Forster, T., Újszászy, L., Farsang, C., Aronson, D., Efrati, S., Freimark, D., Zeltser, D., Gaciong, Z., Skoneczna, I., Drzewiecki, A., Miekus, P., Piepiorka, M., Providência, L, Fonseca, C., Lousada, N., Dorobantu, M., Dimulescu, D., Vintila, M., Dan, A.G., Rotaru, L., Minescu, B., Zdrenghea, D., de Vries Basson, M.M., Roos, J.S., Roodt, A., Wikström, G., Chung, E.S., Gottlieb, S.S., Jain, A., and Pan, D.C.

Published
2011
Full Text
View/download PDF

9. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)

Author

Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, Zamorano, J, Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., Zamorano J. L., Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, Zamorano, J, Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., and Zamorano J. L.

Published
2018

10. 2018 ESC/ESH guidelines for the diagnosis and treatment of arterial hypertension: The Task Force for the Diagnosis and Treatment of Arterial Hypertension of the European Society of Cardiology (ESC) and of the European Society of Hypertension (ESH)

Author

Williams B., Mancia G., Spiering W., Rosei E. A., Azizi M., Burnier M., Clement D. L., Coca A., De Simone G., Dominiczak A., Kahan T., Mahfoud F., Redon J., Ruilope L., Zanchetti A., Kerins M., Kjeldsen S. E., Kreutz R., Laurent S., Lip G. Y. H., McManus R., Narkiewicz K., Ruschitzka F., Schmieder R. E., Shlyakhto E., Tsioufis C., Aboyans V., Desormais I., De Backer G., Heagerty A. M., Agewall S., Bochud M., Borghi C., Boutouyrie P., Brguljan J., Bueno H., Caiani E. G., Carlberg B., Chapman N., Cifkova R., Cleland J. G. F., Collet J. -P., Coman I. M., De Leeuw P. W., Delgado V., Dendale P., Diener H. -C., Dorobantu M., Fagard R., Farsang C., Ferrini M., Graham I. M., Grassi G., Haller H., Richard Hobbs F. D., Jelakovic B., Jennings C., Katus H. A., Kroon A. A., Leclercq C., Lovic D., Lurbe E., Manolis A. J., McDonagh T. A., Messerli F., Muiesan M. L., Nixdorff U., Olsen M. H., Parati G., Perk J., Piepoli M. F., Polonia J., Ponikowski P., Richter D. J., Rimoldi S. F., Roffi M., Sattar N., Seferovic P. M., Simpson I. A., Sousa-Uva M., Stanton A. V., Van De Borne P., Vardas P., Volpe M., Wassmann S., Windecker S., Zamorano J. L., Williams, B, Mancia, G, Spiering, W, Rosei, E, Azizi, M, Burnier, M, Clement, D, Coca, A, De Simone, G, Dominiczak, A, Kahan, T, Mahfoud, F, Redon, J, Ruilope, L, Zanchetti, A, Kerins, M, Kjeldsen, S, Kreutz, R, Laurent, S, Lip, G, Mcmanus, R, Narkiewicz, K, Ruschitzka, F, Schmieder, R, Shlyakhto, E, Tsioufis, C, Aboyans, V, Desormais, I, De Backer, G, Heagerty, A, Agewall, S, Bochud, M, Borghi, C, Boutouyrie, P, Brguljan, J, Bueno, H, Caiani, E, Carlberg, B, Chapman, N, Cifkova, R, Cleland, J, Collet, J, Coman, I, De Leeuw, P, Delgado, V, Dendale, P, Diener, H, Dorobantu, M, Fagard, R, Farsang, C, Ferrini, M, Graham, I, Grassi, G, Haller, H, Richard Hobbs, F, Jelakovic, B, Jennings, C, Katus, H, Kroon, A, Leclercq, C, Lovic, D, Lurbe, E, Manolis, A, Mcdonagh, T, Messerli, F, Muiesan, M, Nixdorff, U, Olsen, M, Parati, G, Perk, J, Piepoli, M, Polonia, J, Ponikowski, P, Richter, D, Rimoldi, S, Roffi, M, Sattar, N, Seferovic, P, Simpson, I, Sousa-Uva, M, Stanton, A, Van De Borne, P, Vardas, P, Volpe, M, Wassmann, S, Windecker, S, and Zamorano, J

Subjects
diagnosis and treatment of arterial hypertension
Published
2018

12. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Author

Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C. W., le Roux, Carel W., Ortiz, Violante, Jensen, Christine Bjorn, Wilding, John P. H., Hamann, A, Barakat, A, Blüher, M, Linn, T, DALLE MOLLE, Alberto, Segner, A, Stübler, P, Tosch-Sisting, R, Pacini, F, Santini, F, Marchesini, G, Rotella, Cm, Invitti, C, Vettor, R, Buscemi, S, Raya, Pm, Freijoo, Fc, de Barbará RG, Carraro, R, Bobillo, Er, de la Cuesta, C, Farsang, C, Csaszar, A, Zahorska-Markiewicz, B, Pupek-Musialik, D, Franek, E, Ostrowska, L, Olszanecka-Glinianowicz, M, Lalic, N, Micic, D, Ludvik, B, Paulweber, B, Prager, R, Scheen, A, Van Gaal, L, Astrup, Av, Hermansen, K, Madsbad, S, Rissanen, A, Nieminen, S, Savolainen, M, Krempf, M, Romon, M, Laville, M, Marre, M, Mira, R, Finucane, F, Veenendaal, A, van Berkum, F, Johannsson-Vidarsdóttir, S, Van de Walle, V, Meesters, E, Hjelmesæth, J, Klemsdal, To, Kulseng, B, Bach-Kliegel, B, Laederach, K, Villiger, L, Golay, A, Bilz, S, Sathyapalan, T, Bain, S, Kumar, S, Le Roux CW, Lean, Me, Mcgowan, B, Rehman, T, Wilding, J, Wittert, G, Caterson, I, Proietto, J, Prins, J, Geloneze Neto, B, Gross, Jl, Chacra, Ar, Halpern, A, Suplicy Hde, A, Chow, Fc, Thacker, Hp, Chadha, M, Chandalia, H, Unnikrishnan, A, Kalra, S, Deshpande, N, Shunmugavelu, M, Deshmukh, Vc, Maislos, M, Lieberman, Gs, Shimon, I, Stern, N, Nabriski, D, Karnieli, E, Shehadeh, N, Gonzalez-Galvez, G, Arechavaleta-Granell Mdel, R, Violante Ortiz RM, Franco, Gm, Gurieva, I, Suplotova, La, Troshina, E, Ruyatkina, La, Voychik, Ea, Martsevich, S, Startseva, Ma, Seeber, Me, Badat, A, Ellis, G, Altuntas, Y, Guler, S, Ulgen, E, Delibasi, T, Chetty, T, Hart, R, Janzen, J, Labonte, I, Lau, D, Liutkus, J, O'Keefe, D, Padwal, R, Ransom, Tp, Tytus, R, Weisnagel, Sj, Adler, J, Aqua, K, Aronoff, Sl, Bedel, Gw, Blevins, Tc, Blumenau, J, Brockmyre, Ap, Call, Rs, Canadas, R, Chaykin, Lb, Cohen, K, Conrow, Jk, Davis, Mg, Downey, Hj, Drosman, Sr, Duckor, S, Farmer, H, Farrell, J, Fehnel, S, Finneran, Mp, Forbes, R, Forker, A, Fredrick, M, Fujioka, K, Geller, Sa, Gill, S, Glaser, L, Greco, Sn, Greenway, Fl, Harper, W, Herman, L, Hoekstra, J, Ingebretsen, R, Ison, R, Jain, Rk, Kaplan, R, Kaster, Sr, Haase, Ga, Kerzner, B, Kirstein, Jl, Koltun, W, Krieger, Dr, Lewis, Ce, Madder, R, Marple, Rn, Mcdermott, Ej, Mello, Cj, Miller, Ab, Mullen, J, Nardandrea, J, O'Neil, P, Pi-Sunyer, F, Pucillo, Rm, Rhee, C, Redrick, S, Pardini, A, Rothman, J, Rubino, Dm, Sellers, G, Smith, T, Byars, Wd, Soufer, J, Sussman, Am, Patrick, K, Schramm, El, Van Cleeff, M, Berg, Sr, Wyatt, Hr, Simon, Ja., Columbia University [New York], Obesity Research Center, The University of Tennessee [Knoxville], Department of Nutrition, Exercise and Sports [Copenhagen], Faculty of Science [Copenhagen], University of Copenhagen = Københavns Universitet (KU)-University of Copenhagen = Københavns Universitet (KU), Scripps Research Institute, Louisiana State University (LSU), Universidade de São Paulo (USP), Centre hospitalier universitaire de Nantes (CHU Nantes), University of Calgary, University College Dublin (UCD), Instituto Mexicano del Seguro Social [Mexico City, Mexico] (IMSS), Novo Nordisk, Department of Obesity and Endocrinology, University of Liverpool, Pi-Sunyer, Xavier, Astrup, Arne, Fujioka, Ken, Greenway, Frank, Halpern, Alfredo, Krempf, Michel, Lau, David C.W., Le Roux, Carel W., Ortiz, Rafael Violante, Jensen, Christine Bjørn, Wilding, John P.H., the SCALE Obesity and Prediabetes NN8022-1839 Study Group [.., Marchesini, Giulio, ], Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D., le Roux, C., Violante Ortiz, R., Jensen, C., Wilding, J. COLLABORATORS: amann A, Barakat A, Blüher M, Linn T, Mölle A, Segner A, Stübler P, Tosch-Sisting R, Pacini F, Santini F, Marchesini G, Rotella CM, Invitti C, Vettor R, Buscemi S, and Raya PM, Freijoo FC, de Barbará RG, Carraro R, Bobillo ER, de la Cuesta C, Farsang C, Csaszar A, Zahorska-Markiewicz B, Pupek-Musialik D, Franek E, Ostrowska L, Olszanecka-Glinianowicz M, Lalic N, Micic D, Ludvik B, Paulweber B, Prager R, Scheen A, Van Gaal L, Astrup AV, Hermansen K, Madsbad S, Rissanen A, Nieminen S, Savolainen M, Krempf M, Romon M, Laville M, Marre M, Mira R, Finucane F, Veenendaal A, van Berkum F, Johannsson-Vidarsdóttir S, Van de Walle V, Meesters E, Hjelmesæth J, Klemsdal TO, Kulseng B, Bach-Kliegel B, Laederach K, Villiger L, Golay A, Bilz S, Sathyapalan T, Bain S, Kumar S, Le Roux CW, Lean ME, McGowan B, Rehman T, Wilding J, Wittert G, Caterson I, Proietto J, Prins J, Geloneze Neto B, Gross JL, Chacra AR, Halpern A, Suplicy Hde A, Chow FC, Thacker HP, Chadha M, Chandalia H, Unnikrishnan A, Kalra S, Deshpande N, Shunmugavelu M, Deshmukh VC, Maislos M, Lieberman GS, Shimon I, Stern N, Nabriski D, Karnieli E, Shehadeh N, Gonzalez-Galvez G, Arechavaleta-Granell Mdel R, Violante Ortiz RM, Franco GM, Gurieva I, Suplotova LA, Troshina E, Ruyatkina LA, Voychik EA, Martsevich S, Startseva MA, Seeber ME, Badat A, Ellis G, Altuntas Y, Guler S, Ulgen E, Delibasi T, Chetty T, Hart R, Janzen J, Labonte I, Lau D, Liutkus J, O'Keefe D, Padwal R, Ransom TP, Tytus R, Weisnagel SJ, Adler J, Aqua K, Aronoff SL, Bedel GW, Blevins TC, Blumenau J, Brockmyre AP, Call RS, Canadas R, Chaykin LB, Cohen K, Conrow JK, Davis MG, Downey HJ, Drosman SR, Duckor S, Farmer H, Farrell J, Fehnel S, Finneran MP, Forbes R, Forker A, Fredrick M, Fujioka K, Geller SA, Gill S, Glaser L, Greco SN, Greenway FL, Harper W, Herman L, Hoekstra J, Ingebretsen R, Ison R, Jain RK, Kaplan R, Kaster SR, Haase GA, Kerzner B, Kirstein JL, Koltun W, Krieger DR, Lewis CE, Madder R, Marple RN, McDermott EJ, Mello CJ, Miller AB, Mullen J, Nardandrea J, O'Neil P, Pi-Sunyer F, Pucillo RM, Rhee C, Redrick S, Pardini A, Rothman J, Rubino DM, Sellers G, Smith T, Byars WD, Soufer J, Sussman AM, Patrick K, Schramm EL, Van Cleeff M, Berg SR, Wyatt HR, Simon JA.

Subjects
Blood Glucose, Counseling, Male, Type 2 diabetes, law.invention, Body Mass Index, Randomized controlled trial, Weight loss, law, Glucagon-Like Peptide 1, Weight management, Subcutaneous, Medicine (all), Reducing, Nausea, General Medicine, Middle Aged, Combined Modality Therapy, 3. Good health, Female, type 2 diabetes, medicine.symptom, Human, medicine.drug, Adult, Diarrhea, medicine.medical_specialty, Diet, Reducing, Injections, Subcutaneous, Injections, Subcutaneou, Placebo, Injections, Double-Blind Method, Internal medicine, Weight Loss, medicine, Humans, Hypoglycemic Agents, Obesity, Exercise, Hypoglycemic Agent, Liraglutide, business.industry, medicine.disease, Weight Lo, Diet, Endocrinology, business, [SDV.AEN]Life Sciences [q-bio]/Food and Nutrition, Body mass index, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Dyslipidemia
Abstract

BACKGROUND: Obesity is a chronic disease with serious health consequences, but weight loss is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like peptide-1 analogue, has been shown to have potential benefit for weight management at a once-daily dose of 3.0 mg, injected subcutaneously. METHODS: We conducted a 56-week, double-blind trial involving 3731 patients who did not have type 2 diabetes and who had a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of at least 30 or a BMI of at least 27 if they had treated or untreated dyslipidemia or hypertension. We randomly assigned patients in a 2:1 ratio to receive once-daily subcutaneous injections of liraglutide at a dose of 3.0 mg (2487 patients) or placebo (1244 patients); both groups received counseling on lifestyle modification. The coprimary end points were the change in body weight and the proportions of patients losing at least 5% and more than 10% of their initial body weight. RESULTS: At baseline, the mean (±SD) age of the patients was 45.1±12.0 years, the mean weight was 106.2±21.4 kg, and the mean BMI was 38.3±6.4; a total of 78.5% of the patients were women and 61.2% had prediabetes. At week 56, patients in the liraglutide group had lost a mean of 8.4±7.3 kg of body weight, and those in the placebo group had lost a mean of 2.8±6.5 kg (a difference of -5.6 kg; 95% confidence interval, -6.0 to -5.1; P

Published
2015
Full Text
View/download PDF

13. Randomized evaluation of a novel, fixed-dose combination of perindopril 3.5mg/amlodipine 2.5mg as a first-step treatment in hypertension

Author

Laurent, S, Parati, G, Chazova, I, Sirenko, Y, Erglis, A, Laucevicius, A, Farsang, C, PARATI, GIANFRANCO, Farsang, C., Laurent, S, Parati, G, Chazova, I, Sirenko, Y, Erglis, A, Laucevicius, A, Farsang, C, PARATI, GIANFRANCO, and Farsang, C.

Abstract

OBJECTIVE:: To evaluate perindopril 3.5mg/amlodipine 2.5mg once daily, a novel fixed-dose combination adapted for first-step treatment in patients with hypertension. This fixed dose had to be equivalent to amlodipine 5mg in terms of blood pressure efficacy, but with an expected better tolerability profile. We selected two drugs with complementary modes of action, with doses chosen so that each drug would contribute similarly to the overall blood pressure-lowering effect METHODS:: An international, randomized, double-blind, placebo-controlled study with six equal parallel treatment arms and an 8-week randomized treatment period, whose design, clinical significance and non-inferiority criteria were in accordance with European guidelines. RESULTS:: In all, 1581 patients with mild-to-moderate uncomplicated hypertension (mean age 51.7 years) were randomized and 94.7% completed the study. The combination was statistically and clinically superior to placebo (between-group differences: SBP: -7.22mmHg, DBP: -4.12mmHg, P<0.001 for both). Rates of response and normalization of blood pressure were greater with the combination (P<0.001 for both) and numerical differences relative to placebo were apparent at 2 weeks. The combination was superior to either component given singly (P<0.001 for both drugs, for SBP and DBP), and was non-inferior to both component drugs given singly at their lowest clinically-approved doses. The components of the combination had similar effects on SBP (perindopril 3.5mg: -16.3mmHg; amlodipine 2.5mg: -16.0mmHg). Adverse events relating to peripheral oedema were less frequent with the combination than with amlodipine 5mg. CONCLUSIONS:: The observed blood pressure-lowering efficacy, rapidity of onset of effect and favourable safety profile of the combination perindopril 3.5mg/amlodipine 2.5mg indicate its potential suitability for use as first-step treatment in hypertension.

Published
2015

14. 2003 European Society of Hypertension???European Society of Cardiology guidelines for the management of arterial hypertension*

Author

MANCIA, GIUSEPPE, Rosei, EA, Cifkova, R, DeBacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, AM, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, McInnes, G, Mallion, JM, Brien, EO, Poulter, NR, Priori, SG, Rahn, KH, Rodicio, JL, Ruilope, LM, Safar, M, Staessen, JA, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, Zannad, F., Mancia, G, Rosei, E, Cifkova, R, Debacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, A, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, Mcinnes, G, Mallion, J, Brien, E, Poulter, N, Priori, S, Rahn, K, Rodicio, J, Ruilope, L, Safar, M, Staessen, J, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, and Zannad, F

Subjects
Physiology, optimal treatment hot, left-ventricular hypertrophy, end-point reduction, target-organ damage, Blood Pressure Determination, Guideline, Clinical practice, isolated systolic hypertension, Risk Assessment, Europe, ambulatory blood-pressure, randomized controlled trial, Hypertension, Internal Medicine, Humans, MED/09 - MEDICINA INTERNA, coronary-heart-disease, intima-media thickness, Cardiology and Cardiovascular Medicine, Risk Reduction Behavior, converting-enzyme-inhibition, Antihypertensive Agents
Abstract

ispartof: Journal of hypertension vol:21 issue:6 pages:1011-1053 ispartof: location:Netherlands status: published

Published
2003
Full Text
View/download PDF

16. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study

Author

Tonstad, S., Farsang, C., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A.P., Silagy, C., van Spiegel, P.I., Astbury, C., Hider, A., Sweet, R., Tonstad, S., Farsang, C., Klaene, G., Lewis, K., Manolis, A., Perruchoud, A.P., Silagy, C., van Spiegel, P.I., Astbury, C., Hider, A., and Sweet, R.

Abstract

Aim To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). Methods Six hundred twenty-nine subjects with CVD who smoked ≥10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary efficacy endpoint: continuous abstinence from smoking from weeks 4 to 7. Secondary endpoints: continuous abstinence (weeks 4-12, 4-26 and 4-52) and weekly point prevalence abstinence. All participants received brief motivational support. Safety was evaluated throughout the study. Results Continuous smoking abstinence rates from weeks 4 to 7 were significantly higher in subjects receiving bupropion SR compared with placebo (43 vs. 19%, odds ratio [OR]=3.27, 95% confidence interval [CI] 2.24-4.84; \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(P{<}0.001\) \end{document}). Continuous abstinence rates from weeks 4 to 26 and 4 to 52 continued to be more than double for bupropion SR compared with placebo (27 vs. 11%; 22 vs. 9%, \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \(P{<}0.001\) \end{document}). Weekly point prevalence abstinence was significantly higher for participants who received bupropion SR compared with placebo at weeks 3, 7, 26 and 52 \batchmode \documentclass[fleqn,10pt,legalpaper]{article} \usepackage{amssymb} \usepackage{amsfonts} \usepackage{amsmath} \pagestyle{empty} \begin{document} \((P{<}0.001)\) \end{document}. In both groups, there were no clinically significant changes in blood pressure and heart rate throughout the treatment phase. Overall, 6% of the participants \batchmode \documentclass[fleqn,10pt,legalpaper]{article}

Published
2017

17. Metabolic profile and control by treatment and relationships with blood pressure values in patients from central and easter European countries: the BP-CARE metaboli study

Author

Seravalle, G, BRAMBILLA, GIANMARIA, Cifkova, R, Laurent, S, Narkiewicz, K, Redon, J, Farsang, C, QUARTI TREVANO, FOSCA ANNA LUISA, MANCIA, GIUSEPPE, GRASSI, GUIDO, Seravalle, G, Brambilla, G, Cifkova, R, Laurent, S, Narkiewicz, K, Redon, J, Farsang, C, QUARTI TREVANO, F, Mancia, G, and Grassi, G

Subjects
Metabolic syndrome
Published
2011

18. 2007 Guidelines for the management of arterial hypertension The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

MANCIA, GIUSEPPE, GRASSI, GUIDO, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Heagerty, AM, Kjeldsen, SE, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, RE, Struijker Boudier, HAJ, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, SD, McGregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, JL, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, LH, Mancia, G, Manolis, A, Nilsson, PM, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, Manolis, AJ, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, n, The task force for the management of arterial hypertension of the European Society of Cardiology, n., University of Zurich, Mancia, G, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A, Kjeldsen, S, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R, Struijker Boudier, H, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, L, Manolis, A, Nilsson, P, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, N, and The task force for the management of arterial hypertension of the European Society of Cardiology, N

Subjects
Pediatrics, medicine.medical_specialty, business.industry, Alternative medicine, 610 Medicine & health, World health, 2705 Cardiology and Cardiovascular Medicine, Organ damage, Europe, Resource (project management), Family medicine, Medical, Health care, Hypertension, medicine, 10209 Clinic for Cardiology, Diagnostic assessment, Humans, Cardiology and Cardiovascular Medicine, business, Hypertension/classification/diagnosis/therapy, Societies, Societies, Medical, Medical literature
Abstract

For several years the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) decided not to produce their own guidelines on the diagnosis and treatment of hypertension but to endorse the guidelines on hypertension issued by the World Health Organization (WHO) and International Society of Hypertension (ISH)1,2 with some adaptation to reflect the situation in Europe. However, in 2003 the decision was taken to publish ESH/ESC specific guidelines3 based on the fact that, because the WHO/ISH Guidelines address countries widely varying in the extent of their health care and availability of economic resource, they contain diagnostic and therapeutic recommendations that may be not totally appropriate for European countries. In Europe care provisions may often allow a more in-depth diagnostic assessment of cardiovascular risk and organ damage of hypertensive individuals as well as a wider choice of antihypertensive treatment. The 2003 ESH/ESC Guidelines3 were well received by the clinical world and have been the most widely quoted paper in the medical literature in the last two years.4 However, since 2003 considerable additional evidence on important issues related to diagnostic and treatment approaches to hypertension has become available and therefore updating of the previous guidelines has been found advisable. In preparing the new guidelines the Committee established by the ESH and ESC has agreed to adhere to the principles informing the 2003 Guidelines, namely 1) to try to offer the best available and most balanced recommendation to all health care providers involved in the management of hypertension, 2) to address this aim again by an extensive and critical review of the data accompanied by a series of boxes where specific recommendations are given, as well as by a concise set of practice recommendations to be published soon thereafter as already done in 2003; …

Published
2007

19. Correction: Effects of verapamil SR and atenolol on 24-Hour blood pressure and heart rate in hypertension patients with coronary artery disease: An international verapamil SR-trandolapril ambulatory monitoring substudy

Author

Denardo, S, Gong, Y, Cooper-DeHoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-DeHoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, L�szl�, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, Pepine, Carl J., Denardo, S, Gong, Y, Cooper-DeHoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-DeHoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, L�szl�, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, and Pepine, Carl J.

Abstract

This corrects the article DOI: 10.1371/journal.pone.0122726

Published
2016

20. Correction: Effects of verapamil SR and atenolol on 24-Hour blood pressure and heart rate in hypertension patients with coronary artery disease: An international verapamil SR-trandolapril ambulatory monitoring substudy

Author

Denardo, Scott J., Denardo, S, Gong, Y, Cooper-DeHoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-DeHoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, Lï¿1⁄2szlï¿1⁄2, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, Pepine, Carl J., Denardo, Scott J., Denardo, S, Gong, Y, Cooper-DeHoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-DeHoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, Lï¿1⁄2szlï¿1⁄2, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, and Pepine, Carl J.

Abstract

This corrects the article DOI: 10.1371/journal.pone.0122726

Published
2016

21. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: Rationale for further study on blood pressure targets of antihypertensive treatment after stroke

Author

Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, STRAMBA-BADIALE, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Guan, T, Zhang, Y, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, Ford, G., MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, STRAMBA-BADIALE, MARCO GIOVANNI, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, SCOTTI, LORENZA, Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, STRAMBA-BADIALE, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Guan, T, Zhang, Y, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, Ford, G., MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, STRAMBA-BADIALE, MARCO GIOVANNI, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, and SCOTTI, LORENZA

Published
2016

25. Effects of verapamil SR and atenolol on 24-hour blood pressure and heart rate in hypertension patients with coronary artery disease: An international verapamil SR-trandolapril ambulatory monitoring substudy

Author

Denardo, S, Gong, Y, Cooper-Dehoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-Dehoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, László, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, Pepine, Carl J., Denardo, S, Gong, Y, Cooper-Dehoff, R, Farsang, C, Keltai, M, Szirmai, L, Messerli, F, Bavry, A, Handberg, E, Mancia, G, Pepine, C, Denardo, Scott J., Gong, Yan, Cooper-Dehoff, Rhonda M., Farsang, Csaba, Keltai, Matyas, Szirmai, László, Messerli, Franz H., Bavry, Anthony A., Handberg, Eileen M., Mancia, Giuseppe, and Pepine, Carl J.

Abstract

Elevated nighttime blood pressure (BP) and heart rate (HR), increased BP and HR variability, and altered diurnal variations of BP and HR (nighttime dipping and morning surge) in patients with systemic hypertension are each associated with increased adverse cardiovascular events. However, there are no reports on the effect of hypertension treatment on these important hemodynamic parameters in the growing population of hypertensive patients with atherosclerotic coronary artery disease (CAD). This was a pre-specified subgroup analysis of the INternational VErapamil SR-Trandolapril STudy (INVEST), which involved 22,576 clinically stable patients aged >50 years with hypertension and CAD randomized to either verapamil SR-oratenolol-based hypertension treatment strategies. The subgroup consisted of 117 patients undergoing 24-hour ambulatory monitoring at baseline and after 1 year of treatment. Hourly systolic and diastolic BP (SBP and DBP) decreased after 1 year for both verapamil SR- and atenolol-based treatment strategies compared with baseline (P<0.0001). Atenolol also decreased hourly HR (P<0.0001). Both treatment strategies decreased SBP variability (weighted standard deviation: P = 0.012 and 0.021, respectively). Compared with verapamil SR, atenolol also increased the prevalence of BP and HR nighttime dipping among prior non-dippers (BP: OR = 3.37; 95% CI: 1.26-8.97; P = 0.015; HR: OR = 4.06; 95% CI: 1.35-12.17; P = 0.012) and blunted HR morning surge (+2.8 vs. +4.5 beats/min/hr; P = 0.019). Both verapamil SR- and especially atenolol-based strategies resulted in favorable changes in ambulatory monitoring parameters that have been previously associated with increased adverse cardiovascular events.

Published
2015

26. Effect of atorvastatin on circulating hsCRP concentrations: a sub-study of the achieve cholesterol targets fast with atorvastatin stratified titration (ACTFAST) study

Author

Gensini, Gian Franco, Gori, Anna Maria, Di Laghi, B., Rostagno, Carlo, Gaw, A., Blanco Colio, L. M., De Teresa, E., Egido, J., Farsang, C., A: Leiter, L., Martineau, P., Nozza, A., and Langer, A.

Subjects
CRP, atorvastatin, nutritional and metabolic diseases, lipids (amino acids, peptides, and proteins), cardiovascular diseases
Published
2010

27. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force documental

Author

Mancia, Giuseppe, Laurent, S, AGABITI ROSEI, Enrico, Ambrosioni, E, Burnier, M, Caulfield, Mj, Cifkova, R, Clément, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, Se, Kiowski, W, Mallion, Jm, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, Mh, Rahn, Kh, Redon, J, Rodicio, J, Ruilope, L, Schmieder, Re, Struijker Boudier HA, Van Zwieten PA, Viigimaa, M, and Zanchetti, A.

Published
2009

28. Where Are We With the Management of Hypertension? From Science to Clinical Practice

Author

Farsang, C, Naditch-Brule, L, Avogaro, A, Ostergren, J, Verdecchia, P, Maggioni, A, van de Borne, P, Lins, R, and Roca-Cusachs, A

Abstract

The management of elevated blood pressure in patients at high cardiovascular risk is still a subject of debate. The authors review current international guidelines and results of large clinical trials and recent meta-analyses to discuss the different approaches in patients at high risk for cardiovascular events. The different treatment options are considered in view of the modern approach and of the different classes of drugs (diuretics, angiotensin-converting enzyme inhibitors, calcium channel blockers, beta-blockers, and angiotensin II receptor blockers) currently in use. A case report is presented as an illustration of the difficulties related to the management of high blood pressure in patients at increased risk. The benefits of the use of 2 medications that include an inhibitor of the renin-angiotensin-aldosterone system and a calcium channel blocker or a diuretic are discussed. Choosing the proper drugs and correct doses are important considerations for the long-term management of hypertension.

Published
2009

29. Guías de práctica clínica para el tratamiento de la hipertensión arterial 2007

Author

Mancia, G, de Backer, G, Dominiczak, A F, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A M, Kjeldsen, S E, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R E, Boudier, H A, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck-Brentano, C, Hellemans, I, Kristensen, S D, McGregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J L, Erdine, S, Kiowski, W, Agabiti-Rosei, E, Ambrosioni, E, Lindholm, L H, Manolis, A, Nilsson, P M, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J M, Manolis, A J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, University of Zurich, and Mancia, G

Subjects
Clinical Trials as Topic, Antihypertensive Agents/therapeutic use, Risk Factors, 10209 Clinic for Cardiology, Humans, 610 Medicine & health, Blood Pressure Determination, Life Style, 2705 Cardiology and Cardiovascular Medicine, Hypertension/complications/*diagnosis/*therapy
Published
2007
Full Text
View/download PDF

30. ESH/ESC 2007 Guidelines for the management of arterial hypertension

Author

Grupo de Trabajo para el Tratamiento de la Hipertensión Arterial de la Sociedad Europea, Sociedad Europea de Cardiología, Mancia, Giuseppe, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, Am, Kjeldsen, Se, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, Re, Boudier, Ha, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, Sd, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, Jl, Erdine, S, Kiowski, W, AGABITI ROSEI, Enrico, Ambrosion, E, Lindholm, Lh, Manolis, A, Nilsson, Pm, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, Jm, Manolis, Aj, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, and Williams, B.

Published
2007

32. Blood pressure and LDL-cholesterol targets for prevention of recurrent strokes and cognitive decline in the hypertensive patient: design of the European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment randomized trial.

Author

Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, SCOTTI, LORENZA, Guan, TR, Rodicio, JL, Ruilope, LM, Schmieder, RE, Manolis, AJ, Ford, G., Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, SCOTTI, LORENZA, Guan, TR, Rodicio, JL, Ruilope, LM, Schmieder, RE, Manolis, AJ, and Ford, G.

Abstract

BACKGROUND AND OBJECTIVES:: The SBP values to be achieved by antihypertensive therapy in order to maximize reduction of cardiovascular outcomes are unknown; neither is it clear whether in patients with a previous cardiovascular event, the optimal values are lower than in the low-to-moderate risk hypertensive patients, or a more cautious blood pressure (BP) reduction should be obtained. Because of the uncertainty whether 'the lower the better' or the 'J-curve' hypothesis is correct, the European Society of Hypertension and the Chinese Hypertension League have promoted a randomized trial comparing antihypertensive treatment strategies aiming at three different SBP targets in hypertensive patients with a recent stroke or transient ischaemic attack. As the optimal level of low-density lipoprotein cholesterol (LDL-C) level is also unknown in these patients, LDL-C-lowering has been included in the design. PROTOCOL DESIGN:: The European Society of Hypertension-Chinese Hypertension League Stroke in Hypertension Optimal Treatment trial is a prospective multinational, randomized trial with a 3×2 factorial design comparing: three different SBP targets (1, <145-135; 2, <135-125; 3, <125mmHg); two different LDL-C targets (target A, 2.8-1.8; target B, <1.8mmol/l). The trial is to be conducted on 7500 patients aged at least 65 years (2500 in Europe, 5000 in China) with hypertension and a stroke or transient ischaemic attack 1-6 months before randomization. Antihypertensive and statin treatments will be initiated or modified using suitable registered agents chosen by the investigators, in order to maintain patients within the randomized SBP and LDL-C windows. All patients will be followed up every 3 months for BP and every 6 months for LDL-C. Ambulatory BP will be measured yearly. OUTCOMES:: Primary outcome is time to stroke (fatal and non-fatal). Important secondary outcomes are: time to first major cardiovascular event; cognitive decline (Montreal Cognitive Assessment

Published
2014

33. Blood pressure and low-density lipoprotein-cholesterol lowering for prevention of strokes and cognitive decline: a review of available trial evidence

Author

Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, SCOTTI, LORENZA, Guan, TR, Rodicio, JL, Ruilope, LM, Schmieder, RE, Manolis, AJ, Ford, G., Zanchetti, A, Liu, L, Mancia, G, Parati, G, Grassi, G, Stramba Badiale, M, Silani, V, Bilo, G, Corrao, G, Zambon, A, Scotti, L, Zhang, X, Wang, H, Zhang, Y, Guan, T, Berge, E, Redon, J, Narkiewicz, K, Dominiczak, A, Nilsson, P, Viigimaa, M, Laurent, S, Agabiti Rosei, E, Wu, Z, Zhu, D, Rodicio, J, Ruilope, L, Martell Claros, N, Pinto, F, Schmieder, R, Burnier, M, Banach, M, Cifkova, R, Farsang, C, Konradi, A, Lazareva, I, Sirenko, Y, Dorobantu, M, Postadzhiyan, A, Accetto, R, Jelakovic, B, Lovic, D, Manolis, A, Stylianou, P, Erdine, S, Dicker, D, Wei, G, Xu, C, Xie, H, Coca, A, O'Brien, J, Ford, G, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, GRASSI, GUIDO, BILO, GRZEGORZ, CORRAO, GIOVANNI, ZAMBON, ANTONELLA, SCOTTI, LORENZA, Guan, TR, Rodicio, JL, Ruilope, LM, Schmieder, RE, Manolis, AJ, and Ford, G.

Abstract

BACKGROUND AND OBJECTIVES:: It is well established by a large number of randomized controlled trials that lowering blood pressure (BP) and low-density lipoprotein cholesterol (LDL-C) by drugs are powerful means to reduce stroke incidence, but the optimal BP and LDL-C levels to be achieved are largely uncertain. Concerning BP targets, two hypotheses are being confronted: first, the lower the BP, the better the treatment outcome, and second, the hypothesis that too low BP values are accompanied by a lower benefit and even higher risk. It is also unknown whether BP lowering and LDL-C lowering have additive beneficial effects for the primary and secondary prevention of stroke, and whether these treatments can prevent cognitive decline after stroke. RESULTS:: A review of existing data from randomized controlled trials confirms that solid evidence on optimal BP and LDL-C targets is missing, possible interactions between BP and LDL-C lowering treatments have never been directly investigated, and evidence in favour of a beneficial effect of BP or LDL-C lowering on cognitive decline is, at best, very weak. CONCLUSION:: A new, large randomized controlled trial is needed to determine the optimal level of BP and LDL-C for the prevention of recurrent stroke and cognitive decline.

Published
2014

34. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, Wood, D., Mancia, G, Fagard, R, Narkiewicz, K, Redon, J, Zanchetti, A, Böhm, M, Christiaens, T, Cifkova, R, De Backer, G, Dominiczak, A, Galderisi, M, Grobbee, D, Jaarsma, T, Kirchhof, P, Kjeldsen, S, Laurent, S, Manolis, A, Nilsson, P, Ruilope, L, Schmieder, R, Sirnes, P, Sleight, P, Viigimaa, M, Waeber, B, Zannad, F, Burnier, M, Ambrosioni, E, Caufield, M, Coca, A, Olsen, M, Tsioufis, C, Van De Borne, P, Zamorano, J, Achenbach, S, Baumgartner, H, Bax, J, Bueno, H, Dean, V, Deaton, C, Erol, C, Ferrari, R, Hasdai, D, Hoes, A, Knuuti, J, Kolh, P, Lancellotti, P, Linhart, A, Nihoyannopoulos, P, Piepoli, M, Ponikowski, P, Tamargo, J, Tendera, M, Torbicki, A, Wijns, W, Windecker, S, Clement, D, Gillebert, T, Rosei, E, Anker, S, Bauersachs, J, Hitij, J, Caulfield, M, De Buyzere, M, De Geest, S, Derumeaux, G, Erdine, S, Farsang, C, Funck Brentano, C, Gerc, V, Germano, G, Gielen, S, Haller, H, Jordan, J, Kahan, T, Komajda, M, Lovic, D, Mahrholdt, H, Ostergren, J, Parati, G, Perk, J, Polonia, J, Popescu, B, Reiner, Ž, Rydén, L, Sirenko, Y, Stanton, A, Struijker Boudier, H, Vlachopoulos, C, Volpe, M, Wood, D, MANCIA, GIUSEPPE, PARATI, GIANFRANCO, and Wood, D.

Published
2013

35. Bupropion SR for smoking cessation in smokers with cardiovascular disease: A multicentre, randomised study.

Author

Sweet R., Manolis A., Perruchoud A.P., Silagy C., Van Spiegel P.I., Astbury C., Hider A., Tonstad S., Farsang C., Klaene G., Lewis K., Sweet R., Manolis A., Perruchoud A.P., Silagy C., Van Spiegel P.I., Astbury C., Hider A., Tonstad S., Farsang C., Klaene G., and Lewis K.

Abstract

Aim: To investigate the safety and efficacy of bupropion sustained release (bupropion SR) in promoting abstinence from smoking in subjects with cardiovascular disease (CVD). Method(s): Six hundred twenty-nine subjects with CVD who smoked >=10 cigarettes/day were randomised in a double-blind, multicentre study to receive bupropion SR (150 mg twice daily) or placebo for 7 weeks, with a follow-up of 52 weeks. Primary efficacy endpoint: continuous abstinence from smoking from weeks 4 to 7. Secondary endpoints: continuous abstinence (weeks 4-12, 4-26 and 4-52) and weekly point prevalence abstinence. All participants received brief motivational support. Safety was evaluated throughout the study. Result(s): Continuous smoking abstinence rates from weeks 4 to 7 were significantly higher in subjects receiving bupropion SR compared with placebo (43 vs. 19%, odds ratio [OR]=3.27, 95% confidence interval [CI] 2.24-4.84; P<0.001). Continuous abstinence rates from weeks 4 to 26 and 4 to 52 continued to be more than double for bupropion SR compared with placebo (27 vs. 11%; 22 vs. 9%, P<0.001). Weekly point prevalence abstinence was significantly higher for participants who received bupropion SR compared with placebo at weeks 3, 7, 26 and 52 (P<0.001). In both groups, there were no clinically significant changes in blood pressure and heart rate throughout the treatment phase. Overall, 6% of the participants (n=36) discontinued study medication due to an adverse event (bupropion SR, n=17; placebo, n=19). Conclusion(s): After 7 weeks of bupropion SR treatment, more than twice as many smokers with CVD had quit smoking at 1 year compared with placebo. The safety profile of bupropion SR was similar to that previously observed in general smoking populations. © 2003 The European Society of Cardiology. Published by Elsevier Science Ltd. All rights reserved.

Published
2012

36. Prevalence and main features of resistant hypertension in central and eastern Europe: the BP-CARE Study

Author

Seravalle, G, Brambilla, G, Cifkova, R, Farsang, C, Laurent, S, Narkiewicz, K, Redon, J, Bombelli, M, Mancia, G, Grassi, G, BRAMBILLA, GIANMARIA, BOMBELLI, MICHELE, MANCIA, GIUSEPPE, GRASSI, GUIDO, Seravalle, G, Brambilla, G, Cifkova, R, Farsang, C, Laurent, S, Narkiewicz, K, Redon, J, Bombelli, M, Mancia, G, Grassi, G, BRAMBILLA, GIANMARIA, BOMBELLI, MICHELE, MANCIA, GIUSEPPE, and GRASSI, GUIDO

Published
2012

37. Study on cognition and prognosis in the elderly (SCOPE): baseline characteristics

Author

HANSSON, L., LITHELL, H., SKOOG, I., BARO, F., BANKI, C.M., BRETELER, M., CASTAIGNE, A., CORREIA, M., DEGAUTE, J.P., ELMFELDT, D., ENGEDAL, K., FARSANG, C., FERRO, J., HACHINSKI, V., HOFMAN, A., JAMES, O.F., KRISIN, E., LEEMAN, M., DE LEEUW, P.W., LEYS, D., LOBO, A., NORDBY, G., OLOFSSON, B., OPOLSKI, G., PRINCE, M., REISCHIES, F.M., and Epidemiology

Subjects
Aged, 80 and over, Male, Aging, Sex Characteristics, Incidence, Biphenyl Compounds, Tetrazoles, Prognosis, Receptor, Angiotensin, Type 2, Receptor, Angiotensin, Type 1, Angiotensin Receptor Antagonists, Cognition, Double-Blind Method, Cardiovascular Diseases, Risk Factors, Humans, Benzimidazoles, Dementia, Female, Cognition Disorders, Antihypertensive Agents, Aged
Abstract

Blood Press. 2000;9(2-3):146-51. Study on COgnition and Prognosis in the Elderly (SCOPE): baseline characteristics. Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M, Castaigne A, Correia M, Degaute JP, Elmfeldt D, Engedal K, Farsang C, Ferro J, Hachinski V, Hofman A, James OF, Krisin E, Leeman M, de Leeuw PW, Leys D, Lobo A, Nordby G, Olofsson B, Opolski G, Prince M, Reischies FM. University of Uppsala, Department of Public Health, Clinical Hypertension Research, Sweden. Abstract The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multi-centre, prospective, randomized, double-blind, parallel-group study. The primary objective of SCOPE is to assess the effect of the angiotensin II type 1 (AT1) receptor blocker, candesartan cilexetil 8-16 mg once daily, on major cardiovascular events in elderly patients (70-89 years of age) with mild hypertension (DBP 90-99 and/or SBP 160-179 mmHg). The secondary objectives of the study are to test the hypothesis that antihypertensive therapy can prevent cognitive decline (as measured by the Mini Mental State Examination, MMSE) and dementia, and to assess the effect of therapy on total mortality, myocardial infarction (MI), stroke, renal function, and hospitalization. A total of 4964 patients from 15 participating countries were recruited during the randomization phase of SCOPE, exceeding the target population of 4000. The mean age of the patients at enrolment was 76 years, the ratio of male to female patients was approximately 1:2, and 52% of patients were already being treated with an antihypertensive agent at enrolment. The majority of patients (88%) were educated to at least primary school level. At randomization, mean sitting blood pressure values were SBP 166 mmHg and DBP 90 mmHg, and the mean MMSE score was 28. Previous cardiovascular disease in the study population included myocardial infarction (4%), stroke (4%) and atrial fibrillation (4%). Men, more often than women, had a history of previous MI, stroke and atrial fibrillation. A greater percentage of men were smokers (13% vs 6% in women) and had attended university (11% vs 3% of women). Of the randomized patients, 21% were 80 years of age. In this age group smoking was less common (4% vs 10% for 70-79-year-olds) and fewer had attended university (4% vs 7% for 70-79-year-olds). The incidence of MI was similar in both age groups. However, stroke and atrial fibrillation had occurred approximately twice as frequently in the older patients. The patients' mean age at baseline was similar in the participating countries, and most countries showed the approximate 1:2 ratio for male to female patients. There was also little inter-country variation in terms of mean SBP, DBP or MMSE score. However, there was considerable regional variation in the percentage of patients on therapy prior to enrolment. PMID: 10855739 [PubMed - indexed for MEDLINE]

Published
2000

38. Blood pressure control and cardiovascular risk profile in hypertensive patients from central and eastern European countries: results of the BP-CARE study

Author

Grassi, G, Cifkova, R, Laurent, S, Narkiewicz, K, Redon, J, Farsang, C, Viigimaa, M, Erdine, S, Brambilla, G, Bombelli, M, Dell'Oro, R, Notari, M, Mancia, G, GRASSI, GUIDO, BOMBELLI, MICHELE, DELL'ORO, RAFFAELLA, MANCIA, GIUSEPPE, Grassi, G, Cifkova, R, Laurent, S, Narkiewicz, K, Redon, J, Farsang, C, Viigimaa, M, Erdine, S, Brambilla, G, Bombelli, M, Dell'Oro, R, Notari, M, Mancia, G, GRASSI, GUIDO, BOMBELLI, MICHELE, DELL'ORO, RAFFAELLA, and MANCIA, GIUSEPPE

Abstract

AimsLimited information is available on office and ambulatory blood pressure (BP) control as well as on cardiovascular (CV) risk profile in treated hypertensive patients living in central and eastern European countries.Methods and resultsIn 2008, a survey on 7860 treated hypertensive patients followed by non-specialist or specialist physicians was carried out in nine central and eastern European countries (Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia, and Ukraine). Cardiovascular risk assessment was based on personal history, clinic BP values, as well as target organ damage evaluation. Patients had a mean (±SD) age of 60.1 ± 11 years, and the majority of them (83.5) were followed by specialists. Average clinic BP was 149.3 ± 17/88.8 ± 11 mmHg. About 70 of patients displayed a very high-risk profile. Electrocardiogram was performed in 99 of patients, echocardiography in 65, carotid ultrasound in 24, fundoscopy in 68, and search for microalbuminuria in 10. Ambulatory BP monitoring was performed in about one-fifth of the recruited patients. Despite the widespread use of combination treatment (87 of the patients), office BP control (<140/90 mmHg) was achieved in 27.1 only, the corresponding control rate for ambulatory BP (<130/80 mmHg) being 35.7. Blood pressure control was (i) variable among different countries, (ii) worse for systolic than for diastolic BP, (iii) slightly better in patients followed by specialists than by non-specialists, (iv) unrelated to patients' age, and (v) more unsatisfactory in high-risk hypertensives and in patients with coronary heart disease, stroke, or renal failure.ConclusionThese data provide evidence that in central and eastern European countries office and ambulatory BP control are unsatisfactory, particularly in patients at very high CV risk, and not differ from that seen in Western Europe. They also show that assessment of subclinical organ damage is quite common, except for microalbuminuria, and t

Published
2011

39. Reappraisal of European guidelines on hypertension management: A European Society of Hypertension Task Force document

Author

Mancia, G, Laurent, S, Agabiti Rosei, E, Ambrosioni, E, Burnier, M, Caulfield, M, Cifkova, R, Clement, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, S, Kiowski, W, Mallion, J, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, M, Rahn, K, Redon, J, Rodicio, J, Ruilope, L, Schmieder, R, Sruijker Boudier, H, Van Zwieten, P, Viigimaa, M, Zanchetti, A, MANCIA, GIUSEPPE, GRASSI, GUIDO, Caulfield, MJ, Kjeldsen, SE, Mallion, JM, Olsen, MH, Rahn, KH, Schmieder, RE, Sruijker Boudier, HAJ, Van Zwieten, PA, Zanchetti, A., Mancia, G, Laurent, S, Agabiti Rosei, E, Ambrosioni, E, Burnier, M, Caulfield, M, Cifkova, R, Clement, D, Coca, A, Dominiczak, A, Erdine, S, Fagard, R, Farsang, C, Grassi, G, Haller, H, Heagerty, A, Kjeldsen, S, Kiowski, W, Mallion, J, Manolis, A, Narkiewicz, K, Nilsson, P, Olsen, M, Rahn, K, Redon, J, Rodicio, J, Ruilope, L, Schmieder, R, Sruijker Boudier, H, Van Zwieten, P, Viigimaa, M, Zanchetti, A, MANCIA, GIUSEPPE, GRASSI, GUIDO, Caulfield, MJ, Kjeldsen, SE, Mallion, JM, Olsen, MH, Rahn, KH, Schmieder, RE, Sruijker Boudier, HAJ, Van Zwieten, PA, and Zanchetti, A.

Published
2009

40. Study on COgnition and Prognosis in the Elderly (SCOPE)

Author

HANSSON, L., LITHELL, H., SKOOG, I., BARO, F, BANKI, C.M., BRETELER, M., CARBONIN, P.U., CASTAIGNE, A., CORREIA, M., DEGAUTE, J.P., ELMFELDT, D., ENGEDAL, K., FARSANG, C., FERRO, J., HACHINSKI, V., HOFMAN, A., JAMES, O.F., KRISIN, E., LEEMAN, M., DE LEEUW, P.W., LEYS, D., LOBO, A., NORDBY, G., OLOFSSON, B., ZANCHETTI, A., and ET AL

Abstract

Blood Press. 1999;8(3):177-83. Study on COgnition and Prognosis in the Elderly (SCOPE). Hansson L, Lithell H, Skoog I, Baro F, Bánki CM, Breteler M, Carbonin PU, Castaigne A, Correia M, Degaute JP, Elmfeldt D, Engedal K, Farsang C, Ferro J, Hachinski V, Hofman A, James OF, Krisin E, Leeman M, de Leeuw PW, Leys D, Lobo A, Nordby G, Olofsson B, Zanchetti A, et al. University of Uppsala, Department of Public Health, Sweden. Abstract The Study on COgnition and Prognosis in the Elderly (SCOPE) is a multicentre, prospective, randomized, double-blind, parallel-group study designed to compare the effects of candesartan cilexetil and placebo in elderly patients with mild hypertension. The primary objective of the study is to assess the effect of candesartan cilexetil on major cardiovascular events. The secondary objectives of the study are to assess the effect of candesartan cilexetil on cognitive function and on total mortality, cardiovascular mortality, myocardial infarction, stroke, renal function, hospitalization, quality of life and health economics. Male and female patients aged between 70 and 89 years, with a sitting systolic blood pressure (SBP) of 160-179 mmHg and/or diastolic blood pressure (DBP) of 90-99 mmHg, and a Mini-Mental State Examination (MMSE) score of 24 or above, are eligible for the study. The overall target study population is 4000 patients, at least 1000 of whom are also to be assessed for quality of life and health economics data. After an open run-in period lasting 1-3 months, during which patients are assessed for eligibility and those who are already on antihypertensive therapy at enrolment are switched to hydrochlorothiazide 12.5 mg o.d., patients are randomized to receive either candesartan cilexetil 8 mg once daily (o.d.) or matching placebo o.d. At subsequent study visits, if SBP remains >160 mmHg, or has decreased by 85 mmHg, study treatment is doubled to candesartan cilexetil 16 mg o.d. or two placebo tablets o.d. Recruitment was completed in January 1999. At that time 4964 patients had been randomized. All randomized patients will be followed for an additional 2 years. If the event rate is lower than anticipated, the follow-up will be prolonged. PMID: 10595696 [PubMed - indexed for MEDLINE]

Published
1999

42. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)

Author

Mancia, G, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A, Kjeldsen, S, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R, Struijker Boudier, H, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, L, Manolis, A, Nilsson, P, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, N, The task force for the management of arterial hypertension of the European Society of Cardiology, N, MANCIA, GIUSEPPE, GRASSI, GUIDO, Heagerty, AM, Kjeldsen, SE, Schmieder, RE, Struijker Boudier, HAJ, Kristensen, SD, McGregor, K, Zamorano, JL, Lindholm, LH, Nilsson, PM, Manolis, AJ, The task force for the management of arterial hypertension of the European Society of Hypertension, n, The task force for the management of arterial hypertension of the European Society of Cardiology, n., Mancia, G, De Backer, G, Dominiczak, A, Cifkova, R, Fagard, R, Germano, G, Grassi, G, Heagerty, A, Kjeldsen, S, Laurent, S, Narkiewicz, K, Ruilope, L, Rynkiewicz, A, Schmieder, R, Struijker Boudier, H, Zanchetti, A, Vahanian, A, Camm, J, De Caterina, R, Dean, V, Dickstein, K, Filippatos, G, Funck Brentano, C, Hellemans, I, Kristensen, S, Mcgregor, K, Sechtem, U, Silber, S, Tendera, M, Widimsky, P, Zamorano, J, Erdine, S, Kiowski, W, Agabiti Rosei, E, Ambrosioni, E, Lindholm, L, Manolis, A, Nilsson, P, Redon, J, Viigimaa, M, Adamopoulos, S, Bertomeu, V, Clement, D, Farsang, C, Gaita, D, Lip, G, Mallion, J, O'Brien, E, Ponikowski, P, Ruschitzka, F, Tamargo, J, van Zwieten, P, Waeber, B, Williams, B, The task force for the management of arterial hypertension of the European Society of Hypertension, N, The task force for the management of arterial hypertension of the European Society of Cardiology, N, MANCIA, GIUSEPPE, GRASSI, GUIDO, Heagerty, AM, Kjeldsen, SE, Schmieder, RE, Struijker Boudier, HAJ, Kristensen, SD, McGregor, K, Zamorano, JL, Lindholm, LH, Nilsson, PM, Manolis, AJ, The task force for the management of arterial hypertension of the European Society of Hypertension, n, and The task force for the management of arterial hypertension of the European Society of Cardiology, n.

Published
2007

46. METABOLIC PROFILE, PATTERNS OF METABOLIC CONTROL BY TREATMENT AND RELATIONSHIPS WITH BLOOD PRESSURE VALUES IN PATIENTS FROM CENTRAL AND EASTERN EUROPEAN COUNTRIES: THE BP-CARE METABOLIC STUDY

Author

Brambilla, G., primary, Seravalle, G., additional, Cifkova, R, additional, Laurent, S., additional, Narkiewicz, K., additional, Redon, J., additional, Farsang, C., additional, Bombelli, M., additional, Giannattasio, C., additional, Mancial, G., additional, and Grassi, G., additional

Published
2011
Full Text
View/download PDF

48. 2003 European society of hypertension - European Society of Cardiology guidelines for the management of arterial hypertension

Author

Mancia, G, Rosei, E, Cifkova, R, Debacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, A, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, Mcinnes, G, Mallion, J, Brien, E, Poulter, N, Priori, S, Rahn, K, Rodicio, J, Ruilope, L, Safar, M, Staessen, J, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, Zannad, F, MANCIA, GIUSEPPE, Rosei, EA, DeBacker, G, Heagerty, AM, McInnes, G, Mallion, JM, Brien, EO, Poulter, NR, Priori, SG, Rahn, KH, Rodicio, JL, Ruilope, LM, Staessen, JA, Zannad, F., Mancia, G, Rosei, E, Cifkova, R, Debacker, G, Erdine, S, Fagard, R, Farsang, C, Heagerty, A, Kawecka Jaszcs, K, Kiowski, W, Kjeldsen, S, Luscher, T, Mcinnes, G, Mallion, J, Brien, E, Poulter, N, Priori, S, Rahn, K, Rodicio, J, Ruilope, L, Safar, M, Staessen, J, van Zwieten, P, Waeber, B, Williams, B, Zanchetti, A, Zannad, F, MANCIA, GIUSEPPE, Rosei, EA, DeBacker, G, Heagerty, AM, McInnes, G, Mallion, JM, Brien, EO, Poulter, NR, Priori, SG, Rahn, KH, Rodicio, JL, Ruilope, LM, Staessen, JA, and Zannad, F.

Published
2003

50. Study on COgnition and Prognosis in the Elderly (SCOPE): baselinecharacteristics.

Author

Hansson, L, Lithell, H, Skoog, I, Baro, F, Banki, CM, Breteler, M, Castaigne, A, Correia, M, Degaute, JP, Elmfeldt, D, Engedal, K, Farsang, C, Ferro, J, Hachinski, V, Hofman, A, James, OF, Krisin, E, Leeman, M, de Leeuw, PW, Leys, D, Lobo, A, Nordby, G, Olofsson, B, Opolski, G, Prince, M, Reischies, FM, Hansson, L, Lithell, H, Skoog, I, Baro, F, Banki, CM, Breteler, M, Castaigne, A, Correia, M, Degaute, JP, Elmfeldt, D, Engedal, K, Farsang, C, Ferro, J, Hachinski, V, Hofman, A, James, OF, Krisin, E, Leeman, M, de Leeuw, PW, Leys, D, Lobo, A, Nordby, G, Olofsson, B, Opolski, G, Prince, M, and Reischies, FM

Published
2000

Catalog

Books, media, physical & digital resources
See catalog results